Blog
Archive: November 2025
Exploring how GLP-1 Drugs and vascular biomarkers are shaping Alzheimer’s Disease clinical trial design
At CTAD 2025, all eyes will be on GLP-1 therapies as Novo Nordisk shares new data from its semaglutide Alzheimer’s programme.
The Emergence of Neuromelanin-Sensitive Imaging in Parkinson’s Clinical Trials
Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) has emerged as a promising biomarker for Parkinson’s disease (PD) research. Historically, imaging in PD has relied primarily on nuclear medicine techniques such as dopamine transporter (DAT) scans, as patients with PD do not exhibit robust, disease-specific patterns of brain atrophy detectable with conventional structural MRI.